肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)

2021-05-15 中国医师协会肿瘤医师分会 中国新药杂志

埃克替尼

中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了《埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)》,希望为埃克替尼规范治疗提供参考。 

中文标题：

埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)

发布机构：

中国医师协会肿瘤医师分会

发布日期：

2021-05-15

简要介绍：

埃克替尼是中国第1个拥有自主知识产权的表皮生长因子受体酪氨酸激酶抑制剂,也是全球第3个上市的表皮生长因子受体酪氨酸激酶抑制剂,自2011年6月7日在中国上市以来已经有近260 000例非小细胞肺癌患者接受了埃克替尼治疗。为了总结埃克替尼上市9年来在中国非小细胞肺癌患者的用药经验,进一步规范埃克替尼的使用,中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了《埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)》,希望为埃克替尼规范治疗提供参考。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=埃克替尼治疗非小细胞肺癌中国专家共识_2021年版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=da1a41c0022a00c4, title=埃克替尼治疗非小细胞肺癌中国专家共识(2021年版), enTitle=, guiderFrom=中国新药杂志, authorId=0, author=, summary=中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了《埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)》,希望为埃克替尼规范治疗提供参考。 , cover=https://img.medsci.cn/20211027/1635324991570_5579292.jpg, journalId=0, articlesId=null, associationId=896, associationName=中国医师协会肿瘤医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Sat May 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">埃克替尼是中国第1个拥有自主知识产权的表皮生长因子受体酪氨酸激酶抑制剂,也是全球第3个上市的表皮生长因子受体酪氨酸激酶抑制剂,自2011年6月7日在中国上市以来已经有近260 000例非小细胞肺癌患者接受了埃克替尼治疗。为了总结埃克替尼上市9年来在中国非小细胞肺癌患者的用药经验,进一步规范埃克替尼的使用,中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了《埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)》,希望为埃克替尼规范治疗提供参考。&nbsp;</span></p>, tagList=[TagDto(tagId=913, tagName=埃克替尼)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=913, guiderKeyword=埃克替尼, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2923, appHits=117, showAppHits=0, pcHits=628, showPcHits=2801, likes=0, shares=21, comments=3, approvalStatus=1, publishedTime=Wed Oct 27 17:41:18 CST 2021, publishedTimeString=2021-05-15, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Oct 27 17:27:53 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 15:29:42 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=埃克替尼治疗非小细胞肺癌中国专家共识_2021年版.pdf)])
埃克替尼治疗非小细胞肺癌中国专家共识_2021年版.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1066229, encodeId=2fe0106622906, content=感谢感谢，正是做课题需要的资料，感谢分享感谢感谢，指南更权威, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008f5685899, createdName=ms6000001241683628, createdTime=Tue Nov 02 14:29:47 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064630, encodeId=bb5010646301f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:30:44 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064435, encodeId=adf310644356d, content=已读真是受益匪浅呀！学习学习已读已读已读已读已读已读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Oct 27 17:51:36 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-11-02 ms6000001241683628

    感谢感谢，正是做课题需要的资料，感谢分享感谢感谢，指南更权威

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1066229, encodeId=2fe0106622906, content=感谢感谢，正是做课题需要的资料，感谢分享感谢感谢，指南更权威, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008f5685899, createdName=ms6000001241683628, createdTime=Tue Nov 02 14:29:47 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064630, encodeId=bb5010646301f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:30:44 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064435, encodeId=adf310644356d, content=已读真是受益匪浅呀！学习学习已读已读已读已读已读已读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Oct 27 17:51:36 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-10-28 1207866fm50(暂无昵称)

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1066229, encodeId=2fe0106622906, content=感谢感谢，正是做课题需要的资料，感谢分享感谢感谢，指南更权威, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008f5685899, createdName=ms6000001241683628, createdTime=Tue Nov 02 14:29:47 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064630, encodeId=bb5010646301f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:30:44 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064435, encodeId=adf310644356d, content=已读真是受益匪浅呀！学习学习已读已读已读已读已读已读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Wed Oct 27 17:51:36 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-10-27 ms5000000518166734

    已读真是受益匪浅呀！学习学习已读已读已读已读已读已读

    0

相关指南

2016 中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）

暂未更新 · 2016-07-01